These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21397779)

  • 1. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study.
    Lu CY; Law MR; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS
    Clin Ther; 2011 Jan; 33(1):135-44. PubMed ID: 21397779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.
    Law MR; Lu CY; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS
    Clin Ther; 2010 Apr; 32(4):729-41; discussion 716. PubMed ID: 20435243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees.
    Adams AS; Zhang F; LeCates RF; Graves AJ; Ross-Degnan D; Gilden D; McLaughlin TJ; Lu C; Trinacty CM; Soumerai SB
    Arch Intern Med; 2009 Apr; 169(8):750-6. PubMed ID: 19398686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness.
    Lu CY; Soumerai SB; Ross-Degnan D; Zhang F; Adams AS
    Med Care; 2010 Jan; 48(1):4-9. PubMed ID: 19956079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence.
    Amin K; Farley JF; Maciejewski ML; Domino ME
    J Manag Care Spec Pharm; 2017 Mar; 23(3):337-345. PubMed ID: 28230447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
    Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
    J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder.
    Zhang Y; Adams AS; Ross-Degnan D; Zhang F; Soumerai SB
    Psychiatr Serv; 2009 Apr; 60(4):520-7. PubMed ID: 19339328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spillover effects of state medicaid antipsychotic prior authorization policies in US commercially insured youth.
    Spence O; Reeves G; dosReis S
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1064-1071. PubMed ID: 32558177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.
    Law MR; Ross-Degnan D; Soumerai SB
    Psychiatr Serv; 2008 May; 59(5):540-6. PubMed ID: 18451014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
    Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
    Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population.
    Hartung DM; Touchette DR; Ketchum KL; Haxby DG; Goldberg BW
    Clin Ther; 2004 Sep; 26(9):1518-32. PubMed ID: 15531015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in nationwide Medicare and Medicaid expenditures on lipid-lowering therapies after proprotein convertase/subtilisin type 9 inhibitor availability.
    Buckley LF; Ting C; Fatani N; Fanikos J
    J Clin Lipidol; 2020; 14(3):315-321.e4. PubMed ID: 32362514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage.
    Adams AS; Madden JM; Zhang F; Soumerai SB; Gilden D; Griggs J; Trinacty CM; Bishop C; Ross-Degnan D
    Med Care; 2014 Aug; 52(8):695-703. PubMed ID: 24988304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population.
    Ferries E; Racsa P; Bizzell B; Rhodes C; Suehs B
    J Manag Care Spec Pharm; 2021 May; 27(5):596-606. PubMed ID: 33908274
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of Transitioning to Medicare Part D on Access to Drugs for Medical Conditions among Dual Enrollees with Cancer.
    Adams AS; Madden JM; Zhang F; Lu CY; Ross-Degnan D; Lee A; Soumerai SB; Gilden D; Chawla N; Griggs JJ
    Value Health; 2017 Dec; 20(10):1345-1354. PubMed ID: 29241894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia.
    Doshi JA; Li P; Desai S; Marcus SC
    J Med Econ; 2017 Dec; 20(12):1252-1260. PubMed ID: 28792299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents.
    Walthour A; Seymour L; Tackett R; Perri M
    Ann Pharmacother; 2010 May; 44(5):809-18. PubMed ID: 20388858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial differences in switching, augmentation, and titration of lipid-lowering agents by Medicare/Medicaid dual-eligible patients.
    Mark TL; Axelsen KJ; Mucha L; Sadkova Y
    Am J Manag Care; 2007 Jun; 13 Suppl 3():S72-9. PubMed ID: 17596115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.